You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Glitazones and the cardiovascular system

Devchand, Pallavi R

Current Opinion in Endocrinology, Diabetes & Obesity:
doi: 10.1097/MED.0b013e3282f79b20
Lipids: Edited by Annabelle Rodriguez

Purpose of review: To chart recent progress on molecular mechanisms of rosiglitazone and pioglitazone in the cardiovascular system.

Recent findings: Several classes of oral antidiabetic drugs are available to treat type 2 diabetes, but glitazones offer the unique promise of insulin-sensitizing ability coupled with potential to reverse cardiovascular abnormalities associated with insulin resistance. Currently the two drugs used are rosiglitazone and pioglitazone, marketed as Avandia and Actos. Recent results of different metaanalyses were inconclusive as to whether rosiglitazone caused real adverse effects of myocardial ischemia. Thus, the US Food and Drugs Administration placed a black box warning on Avandia to signal potential of myocardial infarction and heart-related deaths, as a precautionary measure until analyses of all available data provide clarity. Also unresolved is the extent to which the two compounds share modes of action.

Summary: Type II diabetes affects more than 160 million people, approximately 5% of the world's population ( Recently, questions have been raised about the cardiovascular safety of glitazone antidiabetic drugs. Clearly, there is an urgency to define molecular mechanisms of rosiglitazone and pioglitazone and understand how these drugs may impact patients.

Author Information

Center for Excellence in Vascular Biology, Division of Cardiovascular Medicine, Brigham & Women's Hospital, Harvard University, Boston, Massachusetts, USA

Correspondence to Pallavi R. Devchand, Center for Excellence in Vascular Biology, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, NRB742, Boston, MA 02115 USA Tel: +1 617 525 4374; e-mail:

© 2008 Lippincott Williams & Wilkins, Inc.